Manufacturers report positive results for ruxolitinib cream in atopic dermatitis

Results from the Phase III TruR-AD2 trial found that ruxolitinib was superior to placebo vehicle by at least 2 points in the Investigator’s Global Assessment Treatment Success score. The manufacturers have not yet made a submission for regulatory review for this treatment.


Biospace Inc.